Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Massachusetts and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech’s to large pharmaceutical companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modeling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, please visit www.cyprotex.com.